The transcription factor EHF recruits and activates TAMs via the CCL2/CCR2 axis, remodeling the TME, and serves as a potential prognostic biomarker in cholangiocarcinoma [323]. This evidence concerns the gene CCL2 and cholangiocarcinoma.